A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma - Regional Cancer Care Associates LLC

Clinical Trials

A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Infinity
Protocol Number
IPI-145-19
Cancer Diagnosis
To Learn More Call
201-510-0910